



## Half-year liquidity contract statement

Euronext: MEDCL • Montpellier - France • July 8, 2020 - 7:30 am CEST

---

Under the liquidity contract entered into between MEDINCELL and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30<sup>th</sup> 2020:

- 23,398 shares
- € 174,109.53
- Number of executions on buy side on semester: 791
- Number of executions on sell side on semester: 778
- Traded volume on buy side on semester: 73,482 shares for € 670,186.50
- Traded volume on sell side on semester: 71,922 shares for € 780,030.28

As a reminder:

- the following resources appeared on the last half year statement on December 31<sup>st</sup> 2019 on the liquidity account:
  - 21,838 shares
  - € 64,556.58
  - Number of executions on buy side on semester : 374
  - Number of executions on sell side on semester : 289
  - Traded volume on buy side on semester : 32,784 shares for € 230,115.00
  - Traded volume on sell side on semester : 27,816 shares for € 201,203.25
- the following resources appeared on the liquidity account when the activity started :
  - 0 shares
  - € 200,000.00

The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>791</b>	<b>73,482</b>	<b>670,186.50</b>	<b>778</b>	<b>71,922</b>	<b>780,030.28</b>
02/01/2020	2	251	1,731.90	8	1,199	8,357.03
03/01/2020	7	1,013	6,868.14	1	1	6.90
06/01/2020	4	457	3,093.89	6	750	5,175.00
07/01/2020	2	44	296.56	1	1	6.78
08/01/2020	5	767	5,062.20	1	1	6.60
09/01/2020	1	1	6.68	5	347	2,324.90
10/01/2020	2	600	3,960.00	5	1,023	6,864.33
13/01/2020	1	13	85.80	4	500	3,350.00
14/01/2020	-	-	-	1	15	101.40
15/01/2020	-	-	-	1	116	784.16
16/01/2020	2	21	139.65	1	1	6.76
17/01/2020	2	21	139.44	1	1	6.66
20/01/2020	1	63	418.32	-	-	-
21/01/2020	1	1	6.66	1	1	6.66
22/01/2020	5	485	3,210.70	1	1	6.66
23/01/2020	1	1	6.60	1	1	6.60
24/01/2020	6	725	4,719.75	1	1	6.60
27/01/2020	1	1	6.52	1	1	6.52
28/01/2020	5	387	2,484.54	1	1	6.44
29/01/2020	1	1	6.44	3	251	1,646.56
30/01/2020	1	50	325.00	2	320	2,115.20
31/01/2020	1	1	6.54	1	1	6.54
03/02/2020	3	180	1,170.00	1	1	6.64
04/02/2020	1	1	6.64	3	181	1,205.46
05/02/2020	3	116	755.16	1	1	6.66
07/02/2020	1	1	6.62	1	1	6.62
10/02/2020	2	160	1,040.00	1	1	6.66
11/02/2020	1	1	6.46	1	1	6.46
12/02/2020	-	-	-	1	250	1,650.00
13/02/2020	2	251	1,631.50	2	251	1,656.60
14/02/2020	1	1	6.62	1	1	6.62
18/02/2020	1	1	6.50	-	-	-
19/02/2020	1	1	6.58	1	1	6.58
20/02/2020	1	1	6.60	1	1	6.60
21/02/2020	1	1	6.58	1	1	6.58
25/02/2020	2	51	336.60	5	266	1,771.56

26/02/2020	6	451	2,976.60	5	735	4,917.15
27/02/2020	1	1	6.72	2	196	1,324.96
28/02/2020	5	501	3,316.62	1	1	6.70
02/03/2020	1	1	6.62	3	223	1,494.10
03/03/2020	-	-	-	2	78	525.72
04/03/2020	1	1	6.68	1	1	6.68
06/03/2020	11	934	6,127.04	1	5	33.00
09/03/2020	1	1	6.58	3	246	1,623.60
10/03/2020	6	652	4,224.96	1	1	6.58
11/03/2020	3	601	3,798.32	1	1	6.50
12/03/2020	3	300	1,872.00	-	-	-
13/03/2020	16	3,263	19,382.22	1	75	472.50
16/03/2020	24	2,601	13,161.06	1	1	5.40
17/03/2020	4	300	1,341.00	7	727	3,722.24
19/03/2020	1	1	5.04	5	322	1,719.48
20/03/2020	1	100	520.00	6	402	2,182.86
23/03/2020	2	51	270.30	1	1	5.46
24/03/2020	1	1	5.32	3	52	286.00
25/03/2020	1	150	795.00	5	488	2,674.24
26/03/2020	-	-	-	10	911	5,174.48
27/03/2020	-	-	-	3	272	1,577.60
30/03/2020	-	-	-	8	728	4,302.48
01/04/2020	1	1	5.94	1	1	5.94
02/04/2020	1	1	5.94	1	1	5.94
03/04/2020	-	-	-	6	338	2,034.76
06/04/2020	-	-	-	4	188	1,141.16
07/04/2020	-	-	-	68	9,600	97,056.00
08/04/2020	-	-	-	74	6,400	128,000.00
14/04/2020	17	700	9,660.00	2	155	2,331.20
15/04/2020	22	1,700	21,930.00	8	445	6,283.40
16/04/2020	34	2,300	27,025.00	56	3,304	44,108.40
17/04/2020	19	1,300	16,458.00	8	453	6,065.67
20/04/2020	11	700	8,540.00	4	156	2,087.28
21/04/2020	28	1,600	17,648.00	58	4,587	60,273.18
22/04/2020	16	1,500	19,320.00	12	800	10,888.00
23/04/2020	73	5,400	68,526.00	35	2,300	33,465.00
24/04/2020	7	600	6,492.00	13	400	4,660.00
27/04/2020	4	400	4,300.00	2	100	1,180.00
28/04/2020	34	2,700	30,915.00	35	2,900	35,496.00
30/04/2020	5	500	5,300.00	1	100	1,145.00
04/05/2020	35	2,700	25,785.00	19	1,100	10,780.00
05/05/2020	8	400	3,840.00	5	287	2,832.69

06/05/2020	28	2,202	22,658.58	56	5,300	61,692.00
07/05/2020	34	3,398	33,606.22	6	1,200	12,216.00
08/05/2020	6	500	4,990.00	9	900	9,297.00
11/05/2020	19	2,000	19,040.00	-	-	-
12/05/2020	17	2,400	20,712.00	-	-	-
13/05/2020	21	2,300	19,021.00	43	6,300	59,472.00
14/05/2020	6	950	8,284.00	2	200	1,860.00
15/05/2020	13	1,900	16,511.00	1	200	1,904.00
18/05/2020	9	1,000	8,640.00	-	-	-
19/05/2020	10	800	6,792.00	-	-	-
20/05/2020	7	800	6,520.00	13	1,900	17,879.00
21/05/2020	5	800	7,280.00	-	-	-
22/05/2020	11	601	5,439.05	1	1	9.20
25/05/2020	2	400	3,500.00	-	-	-
26/05/2020	-	-	-	1	200	1,820.00
27/05/2020	6	1,000	8,680.00	-	-	-
28/05/2020	7	800	7,160.00	13	2,000	18,400.00
29/05/2020	5	600	5,220.00	-	-	-
01/06/2020	4	200	1,700.00	-	-	-
02/06/2020	4	400	3,420.00	4	400	3,540.00
03/06/2020	10	600	5,094.00	3	200	1,720.00
04/06/2020	13	1,200	9,780.00	5	800	6,632.00
05/06/2020	21	3,200	25,152.00	11	1,600	13,040.00
08/06/2020	8	650	5,505.50	15	1,400	12,082.00
09/06/2020	3	400	3,380.00	4	450	3,888.00
10/06/2020	1	200	1,740.00	7	600	5,286.00
11/06/2020	7	600	5,100.00	-	-	-
12/06/2020	1	200	1,680.00	1	200	1,720.00
15/06/2020	8	1,300	10,803.00	-	-	-
16/06/2020	1	200	1,620.00	2	200	1,660.00
17/06/2020	1	200	1,680.00	6	900	7,677.00
18/06/2020	2	400	3,300.00	-	-	-
19/06/2020	1	200	1,660.00	5	400	3,380.00
23/06/2020	4	400	3,260.00	-	-	-
24/06/2020	1	200	1,600.00	-	-	-
25/06/2020	4	400	3,140.00	2	321	2,580.84
26/06/2020	1	200	1,560.00	-	-	-
29/06/2020	10	1,200	9,144.00	5	810	6,318.00
30/06/2020	6	600	4,680.00	14	869	6,908.55

## About MedinCell

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.

---

## Contacts

### MedinCell

David Heuzé  
Communication leader  
david.heuze@medincell.com  
+33 (0)6 83 25 21 86

### NewCap

Louis-Victor Delouvrier  
Investor Relations  
medincell@newcap.eu  
+33 (0)1 44 71 98 53

### NewCap

Nicolas Merigeau  
Media Relations  
medincell@newcap.eu  
+33 (0)1 44 71 94 98